Publication

Understanding the Challenges of Adjuvant Treatment Measurement and Reporting in Breast Cancer Cancer Treatment Measuring and Reporting

Publications associées (31)

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

Immune checkpoint blockade (ICB) with antibodies has shown durable clinical responses in a wide range of cancer types, but the overall response rate is still limited. Other effective therapeutic modalities to increase the ICB response rates are urgently ne ...

TAYLOR & FRANCIS INC2023

Pan-cancer atlas of somatic core and linker histone mutations

Sebastian Martin Waszak

Recent genomic data points to a growing role for somatic mutations altering core histone and linker histone-encoding genes in cancer. However, the prevalence and the clinical and biological implications of histone gene mutations in malignant tumors remain ...

2023

Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis

Bart Deplancke, Jorieke Weiden, Guido Van Mierlo

Adoptive T cell therapyhas successfully been implementedfor thetreatment of cancer. Nevertheless, ex vivo expansion of T cells byartificial antigen-presenting cells (aAPCs) remains cumbersome andcan compromise T cell functionality, thereby limiting their t ...

AMER CHEMICAL SOC2023

Metabolic dependencies of metastasis-initiating cells in breast cancer

Candice Megan T Young

Metastasis is the process by which cancer cells from the primary tumor travel through the blood stream to generate a secondary tumor site in a distant organ. Although very few cells are able to make this journey, the resulting effects are dire since most c ...

EPFL2023

Translational screening platform to evaluate chemotherapy in combination with focal therapy for retinoblastoma

Valentin Simeonov, Paul Joseph Dyson, Fabien Kuttler, Patrik Aouad, Irina Sinenko

Retinoblastoma is the most common pediatric eye cancer. It is currently treated with a limited number of drugs, adapted from other pediatric cancer treatments. Drug toxicity and relapse of the disease warrant new therapeutic strategies for these young pati ...

WILEY2023

Nanotechnology enabled modulation of T cell immunity for cancer treatment

Xiaomeng Hu

Recent breakthroughs in cancer immunotherapy, exemplified by immune checkpoint blockade and CAR T cell therapy, have achieved remarkable clinical success. However, the majority of cancer patients fail to respond to immunotherapy or suffer from relapse. Nan ...

EPFL2023

Elucidating and modulating regulatory pathways so as to reprogram the immunosuppressive tumor microenvironment for therapeutic benefit

Agnieszka Alicja Chryplewicz

Glioblastoma (GBM) is the most frequent and highly malignant form of brain cancer. New therapeutic regimens are urgently needed as GBM patients present with a minimal response to currently-approved therapies. The goal of this project is to identify new the ...

EPFL2023

Tumor dormancy: EMT beyond invasion and metastasis

Cathrin Brisken, Patrik Aouad, Hazel Margaret Quinn

More than two-thirds of cancer-related deaths are attributable to metastases. In some tumor types metastasis can occur up to 20 years after diagnosis and successful treatment of the primary tumor, a phenomenon termed late recurrence. Metastases arise from ...

WILEY2023

Comparative Evaluation of Lipofectamine and Dendrimer for Transfection of Short RNA Into Human T47D and MCF-10A Cell Lines

Erfan Shirzadi

Purpose: Non-viral transfection approaches are extensively used in cancer therapy. The future of cancer therapy lies on targeted and efficient drug/gene delivery. The aim of this study was to determine the transfection yields of two commercially available ...

2023

TGF beta-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression

Cathrin Brisken, Andrea Agnoletto

Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. Virtually all women with DCIS are treated, despite evidence suggesting up to half would remain with stable, non-threatening, disease. Overtreatment thus presents a press ...

NATURE PORTFOLIO2023

Highly effective adoptive t cell therapy

Li Tang, Yugang Guo, Bing Feng

The present invention relates generally to the field of anti-cancer therapy and autoimmune therapy, in particular to the use of adoptive T cell transfer therapy. More specifically, the present invention relates to compositions, pharmaceutical compositions ...

2023